Proton Therapy At Siteman Cancer Center: The State Of The Art

被引:4
|
作者
Bloch, Charles [1 ]
机构
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
关键词
Proton radiation therapy; superconducting synchrocyclotron;
D O I
10.1063/1.3586128
中图分类号
O59 [应用物理学];
学科分类号
摘要
Barnes-Jewish Hospital is on the verge of offering proton radiation therapy to its patients. Those treatments will be delivered from the first Monarch 250, a state-of-the-art cyclotron produced by Still River Systems, Inc., Littleton, MA. The accelerator is the world's first superconducting synchrocyclotron, with a field-strength of 10 tesla, providing the smallest accelerator for high-energy protons currently available. On May 14, 2010 it was announced that the first production unit had successfully extracted 250 MeV protons. That unit is scheduled for delivery to the Siteman Cancer Center, an NCI-designated Comprehensive Cancer Center at Washington University School of Medicine. At a weight of 20 tons and with a diameter of less than 2 meters the compact cyclotron will be mounted on a gantry, another first for proton therapy systems. The single-energy system includes 3 contoured scatterers and 14 different range modulators to provide 24 distinct beam delivery configurations. This allows proton fields up to 25cm in diameter, with a maximum range from 5.5 to 32 cm and spread-out-Bragg-peak extent up to 20cm. Monte Carlo simulations have been run using MCNPX to simulate the clinical beam properties. Those calculations have been used to commission a commercial treatment planning system prior to final clinical measurements. MCNPX was also used to calculate the neutron background generated by protons in the scattering system and patient. Additional details of the facility and current status will be presented.
引用
收藏
页码:397 / 400
页数:4
相关论文
共 50 条
  • [1] Proton imaging applications for proton therapy: State of the art
    Amblard, R.
    Floquet, V.
    Angellier, G.
    Hannoun-Levi, J. -M.
    Herault, J.
    CANCER RADIOTHERAPIE, 2015, 19 (02): : 155 - 156
  • [2] Alvin J. Siteman Cancer Center: Cancer Prevention Perspective
    Colditz, Graham A.
    Drake, Bettina F.
    Eberlein, Timothy J.
    CANCER PREVENTION RESEARCH, 2023, 16 (10) : 541 - 544
  • [3] Joanne Knight Breast Health Cohort at Siteman Cancer Center
    Colditz, Graham A.
    Bennett, Debbie L.
    Tappenden, Jennifer
    Beers, Courtney
    Ackermann, Nicole
    Wu, Ningying
    Luo, Jingqin
    Humble, Sarah
    Linnenbringer, Erin
    Davis, Kia
    Jiang, Shu
    Toriola, Adetunji T.
    CANCER CAUSES & CONTROL, 2022, 33 (04) : 623 - 629
  • [4] Joanne Knight Breast Health Cohort at Siteman Cancer Center
    Graham A. Colditz
    Debbie L. Bennett
    Jennifer Tappenden
    Courtney Beers
    Nicole Ackermann
    Ningying Wu
    Jingqin Luo
    Sarah Humble
    Erin Linnenbringer
    Kia Davis
    Shu Jiang
    Adetunji T. Toriola
    Cancer Causes & Control, 2022, 33 : 623 - 629
  • [5] Proton Therapy For Lymphomas: Current State Of The Art
    Ricardi, Umberto
    Maraldo, Maja, V
    Levis, Mario
    Parikh, Rahul R.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8033 - 8046
  • [6] STATE-OF-THE-ART IN PROTON THERAPY TECHNIQUES
    KHOROSHKOV, VS
    ONOSOVSKY, KK
    INSTRUMENTS AND EXPERIMENTAL TECHNIQUES, 1995, 38 (02) : 149 - 158
  • [7] THE ART OF CARING FOR THE PEDIATRIC ANESTHESIA PATIENT IN THE PROTON THERAPY CENTER
    Flores, Leo
    Vanderhorst, Kimberly
    Rosenthal, Yvette
    Venkatasen, Jey
    JOURNAL OF PERIANESTHESIA NURSING, 2023, 38 (04) : E9 - E9
  • [8] State of the Art in Colon Cancer Therapy
    Ghadimi, M.
    Reinacher-Schick, A.
    Blaeker, H.
    Hoeffken, K.
    ONKOLOGE, 2021, 27 (03): : 192 - 194
  • [9] Proton beam radiotherapy for esophagus cancer: state of the art
    Gergelis, Kimberly R.
    Jethwa, Krishan R.
    Tryggestad, Erik J.
    Ashman, Jonathan B.
    Haddock, Michael G.
    Hallemeier, Christopher L.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (11) : 7002 - 7010
  • [10] National Cancer Center has started proton therapy
    Ogino, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1999, 29 (03) : 179 - 179